ArticleCureus2025
Lenvatinib-Associated Vaginal Necrosis and Rectovaginal Fistula After Brachytherapy.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Case Report: Lenvatinib-induced lichenoid drug reaction mimicking disseminated zoster in a patient with metastatic hepatocellular carcinoma.Frontiers in oncology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Lenvatinib and radiotherapy, including brachytherapy, are treatment options for patients with endometrial cancer. However, it is unclear if lenvatinib can induce ulceration and necrosis in patients who have previously received brachytherapy. Here, we describe the case of a 63-year-old woman with endometrial cancer who developed postoperative vaginal wall recurrence and received brachytherapy. One year later, she was given lenvatinib, and two months later, she developed radiation-induced vaginal necrosis, which rapidly progressed to rectovaginal fistula. This case shows that physicians should be aware of the possibility of vaginal necrosis in the administration of lenvatinib to patients who have previously undergone radiotherapy including brachytherapy for the uterus or vagina.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.